Results 261 to 270 of about 10,004,929 (375)

Olaparib synergy screen reveals Exemestane induces replication stress in triple‐negative breast cancer

Molecular Oncology, EarlyView.
Screening 166 FDA‐approved anticancer drugs identifies the aromatase inhibitor Exemestane as a synergistic partner of PARP inhibitor Olaparib in BRCA‐proficient triple‐negative breast cancer. Exemestane induces ROS‐mediated replication stress, enhancing DNA damage and apoptosis alongside Olaparib.
Nur Aininie Yusoh, Liping Su, Suet Lin Chia, Xiaohe Tian, Haslina Ahmad, Martin R. Gill   +5 more
wiley   +1 more source

Japan society of clinical oncology position paper on appropriate clinical use of molecular residual disease (MRD) testing. [PDF]

Int J Clin Oncol
Kobayashi S, Nakamura Y, Hashimoto T, Bando H, Oki E, Karasaki T, Horinouchi H, Ozaki Y, Iwata H, Kato T, Miyake H, Ohba A, Ikeda M, Chiyoda T, Hasegawa K, Fujisawa T, Matsuura K, Namikawa K, Yajima S, Yoshino T, Hasegawa K.   +20 more
europepmc   +1 more source

Acute Myeloid Leukemia Clinical Practice Guidelines in Oncology [PDF]

, 2003

openalex   +1 more source

Pericytes change function depending on glioblastoma vicinity: emphasis on immune regulation

Molecular Oncology, EarlyView.
Pericytes alter their transcriptome depending on their proximity to the tumor core. In the tumor core, pericytes display a more active state with higher communication strength but with lower immune activation potential and a shift toward extracellular matrix production.
Carolina Buizza, Robert Carlsson, Coralie Gamper, Gayatri Chitale, Johan Bengzon, Gesine Paul   +5 more
wiley   +1 more source

Analytical and Clinical Validation of Solo-Test Driver: A Targeted Amplicon-Based NGS Test-System for FFPE and cfDNA Analysis in Clinical Oncology Setting. [PDF]

J Clin Lab Anal
Ivanov M, Lebedeva A, Belova E, Grigoreva T, Veselovsky E, Kavun A, Taraskina A, Kuznetsova O, Nikulin V, Belyaeva L, Kravchuk D, Lisitsa T, Barinov A, Pospekhova N, Aliyarova S, Khomenko E, Tryakin A, Demidova I, Stroganova A, Fedyanin M, Mileyko V.   +20 more
europepmc   +1 more source

WW2: USING LINKABLE CLINICAL AND ADMINISTRATIVE CLAIMS DATA TO IMPROVE OUTCOMES RESEARCH: SELECTED CASE STUDIES FROM ONCOLOGY AND DIABETES MELLITUS

, 2001
Joseph Menzin, Katie Lang
openalex   +1 more source

American Society of Clinical Oncology Treatment of Unresectable Non–Small-Cell Lung Cancer Guideline: Update 2003 [PDF]

, 2003
David G. Pfister, David H. Johnson, Christopher G. Azzoli, William T. Sause, Thomas J. Smith, Sherman Baker, Jemi Olak, Diane E. Stover, John R. Strawn, Andrew T. Turrisi, Mark R. Somerfield   +10 more
openalex   +1 more source

RKIP overexpression reduces lung adenocarcinoma aggressiveness and sensitizes cells to EGFR‐targeted therapies

Molecular Oncology, EarlyView.
RKIP, a metastasis suppressor protein, modulates key oncogenic pathways in lung adenocarcinoma. In silico analyses linked low RKIP expression to poor survival. Functional studies revealed RKIP overexpression reduces tumor aggressiveness and enhances sensitivity to EGFR‐targeted therapies, while its loss promotes resistance.
Ana Raquel‐Cunha, Joana Pinheiro, Rui F. Marques, Patrícia Fontão, Diana Cardoso‐Carneiro, Adriana Mendes, Izabela N. F. Gomes, Ana Carolina Laus, Renato J. da Silva‐Oliveira, Rui Manuel Reis, Olga Martinho   +10 more
wiley   +1 more source

Chinese Society of Clinical Oncology (CSCO) Breast Cancer guidelines 2024. [PDF]

Transl Breast Cancer Res
Li J, Hao C, Wang K, Zhang J, Chen J, Liu Y, Nie J, Yan M, Liu Q, Geng C, Wang X, Wang H, Wang S, Wu J, Yin Y, Song E, Jiang Z.   +16 more
europepmc   +1 more source

Is Patient Travel Distance Associated With Survival on Phase II Clinical Trials in Oncology? [PDF]

, 2003
Elizabeth B. Lamont, Davinder Hayreh, Kate E. Pickett, James J. Dignam, Marcy A. List, Kerstin Stenson, Daniel J. Haraf, Bruce Brockstein, Sarah A. Sellergren, Everett E. Vokes   +9 more
openalex   +1 more source